Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ophthalmic Nerve

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: Ophthalmic Nerve. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-004852-52 Sponsor Protocol Number: OPHT-141117 Start Date*: 2018-04-17
    Sponsor Name:Medical University of Vienna, Department of Clinical Pharmacology
    Full Title: The effect of Tetrahydrocannabinol on ocular hemodynamics in healthy subjects
    Medical condition: The study will be carried out in healthy subjects.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005896-14 Sponsor Protocol Number: Version 1.0 Start Date*: 2006-02-20
    Sponsor Name:Department of Clinical Pharmacology
    Full Title: Role of endothelin- and nitric oxide-system in the regulation of optic nerve head blood flow during changes in ocular perfusion pressure
    Medical condition: 18 healthy male volunteers Age 18-35 yrs., nonsmokers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003278-10 Sponsor Protocol Number: 192024-056 Start Date*: Information not available in EudraCT
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicenter, Double-masked, Randomized, Active-controlled, Parallel Study of the Safety and Efficacy of Once-daily Bimatoprost Preservative-free Ophthalmic Solution Compared to Twice-daily Timolo...
    Medical condition: Glaucoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10018304 Glaucoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004862-33 Sponsor Protocol Number: BCBe/04/Neb-Gla/081 Start Date*: 2006-05-23
    Sponsor Name:Berlin-Chemie Menarini
    Full Title: INFLUENCE OF NEBIVOLOL ON OCULAR PERFUSION IN PATIENTS WITH ARTERIAL HYPERTENSION AND GLAUCOMA A mono-center, active-substance controlled, randomized, double-blind, prospective phase IV parallel-g...
    Medical condition: Arterial hypertension and glaucoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004980-39 Sponsor Protocol Number: Amiloride02 Start Date*: 2013-01-21
    Sponsor Name:University of Oxford
    Full Title: A double blind randomised controlled trial on neuroprotection of amiloride in optic neuritis
    Medical condition: Optic Neuritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-001640-22 Sponsor Protocol Number: C-12-009 Start Date*: 2013-03-25
    Sponsor Name:Alcon Research Ltd
    Full Title: An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients
    Medical condition: Paediatric glaucoma
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-005895-34 Sponsor Protocol Number: VER1.0 Start Date*: 2006-06-05
    Sponsor Name:Department of Clinical Pharmacology, Medical University of Vienna
    Full Title: Effects of common topical glaucoma therapy on optic nerve head blood flow autoregulation during increased arterial blood pressure and artificially elevated intraocular pressure in healthy humans
    Medical condition: only healthy volunteers are included
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004271-12 Sponsor Protocol Number: NGF0213 Start Date*: 2014-01-17
    Sponsor Name:Dompé s.p.a
    Full Title: An open-label study evaluating safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops at different doses in patients with Dry Eye
    Medical condition: Dry Eye syndrome is caused by either decreased tear production or increased tear film evaporation. Dry eye is a chronic inflammatory condition of the ocular surface with severe symptoms and visual ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10013777 Dry eye syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003816-21 Sponsor Protocol Number: RDG-10298 Start Date*: 2012-01-11
    Sponsor Name:S.A. Alcon-Couvreur N.V
    Full Title: Multi-Center Study Assessing Efficacy and Tolerability of TRAVATAN® Solution without BAK, containing Polyquad® Preservative (0.004% travoprost) in Patients Previously on latanoprost 0.005% or bimat...
    Medical condition: Open angle Glaucoma Ocular Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    14.0 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003749-39 Sponsor Protocol Number: NGF0221 Start Date*: 2021-12-15
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL ophthalmic solution versus vehicle, in patients with s...
    Medical condition: Severe Sjogren’s dry eye disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-004201-29 Sponsor Protocol Number: CM-05-08/HU Start Date*: 2006-06-01
    Sponsor Name:Alcon Hungarian ltd
    Full Title: THE EFFICACY AND SAFETY OF TIMOLOL MALEATE 0.5% COMPARED TO BRINZOLAMIDE 1% EACH GIVEN TWICE DAILY WHEN ADDED TO TRAVOPROST 0.004% GIVEN EACH EVENING IN PRIMARY OPEN-ANGLE GLAUCOMA OR OCULAR HYPERT...
    Medical condition: Increased intraocular pressure and glaucoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006718-10 Sponsor Protocol Number: Alcon SMA-08-16 Start Date*: 2009-08-17
    Sponsor Name:Alcon Laboratories, Inc.
    Full Title: The Efficacy and Safety of Travoprost 0.004% versus Tafluprost 0.005% in Primary Open-Angle Glaucoma or Ocular Hypertensive Patients.
    Medical condition: primary open-angle glaucoma ocular hypertension pigment dispersion glaucoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017789-22 Sponsor Protocol Number: OPHT-080210 Start Date*: 2010-05-19
    Sponsor Name:Ursapharm Arzneimittel GmbH
    Full Title: A randomized, placebo-controlled study investigating the effects of moxaverine on ocular blood flow after oral administration in healthy subjects
    Medical condition: healthy subjects
    Disease: Version SOC Term Classification Code Term Level
    12.1 10038881 Retinal microcirculation disorder LLT
    12.1 10030067 Ocular vascular disorders NEC HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002436-82 Sponsor Protocol Number: EC11-441 Start Date*: 2012-12-13
    Sponsor Name:Isabel Pinilla Lozano
    Full Title: Melatonin effects on visual and sleep patterns anomalies in subjects diagnosed with Retinitis Pigmentosa
    Medical condition: To evaluate the sleep quality in patients with Retinitis Pigmentosa
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002821-31 Sponsor Protocol Number: AKST4290-206 Start Date*: 2019-10-10
    Sponsor Name:Alkahest, Inc
    Full Title: The Effect of AKST4290 on Choroidal Blood Flow in Patients with Neovascular Age-Related Macular Degeneration
    Medical condition: Age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001662-35 Sponsor Protocol Number: BTIIMD-02-EC/22/GLAUCOMA Start Date*: 2022-08-18
    Sponsor Name:BTI I MAS D S.L.
    Full Title: Randomized, double-blind, parallel group clinical trial to evaluate the efficacy and safety of PRGF eye drops as a treatment for dry eye disease in patients with glaucoma
    Medical condition: Dry eye disease in patients with glaucoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000385-22 Sponsor Protocol Number: RF-2010-2318561 Start Date*: 2014-10-07
    Sponsor Name:Ospedale San Raffaele di Milano
    Full Title: Nerve Growth Factor eye drops as a novel treatment for vision loss in patients with Retinitis Pigmentosa: from preclinical to clinical Phase II trial.
    Medical condition: Retinitis pigmentosa with cystoid macular edema
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004853 10054467 Macular edema LLT
    17.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002666-47 Sponsor Protocol Number: SOAP1 Start Date*: 2017-11-02
    Sponsor Name:Dpt. of Ophthalmology, Rigshospitalet-Glostrup
    Full Title: Effect of drop-less surgery compared to topical NSAID alone and combination of steroid and NSAID on central macular thickness after cataract surgery, a randomized controlled trial
    Medical condition: Postoperative cystoid macular edema following cataract surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10070634 Irvine-Gass syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-004157-66 Sponsor Protocol Number: QRK202 Start Date*: 2012-05-29
    Sponsor Name:Quark Pharmaceuticals, Inc.
    Full Title: An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined With A Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating The Efficacy and Safety...
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003346-21 Sponsor Protocol Number: NGF0121 Start Date*: 2021-11-24
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution versus vehicle, in patients with se...
    Medical condition: Severe Sjogren’s dry eye disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10040766 Sjogren's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:56:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA